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 2 
Abstract (199)) 32 
BACKGROUND: We studied LGALS13 [Placental Protein 13 (PP13)] promoter DNA 33 
polymorphisms in preeclampsia (PE) prediction, given PP13’s effects on hypotension, 34 
angiogenesis and immunotolerance.  35 
METHODS: We retrieved 67 PE (49 term, 18 preterm) cases and 196 matched controls 36 
from first trimester plasma samples prospectively collected at King's College Hospital, 37
London. Cell-free DNA was extracted and the four LGALS13 exons were sequenced 38 
after PCR amplification. Expression of LGALS13 promoter reporter constructs were 39 
determined in BeWo trophoblast-like cells with luciferase assays.  40 
RESULTS: A/C genotype in –98 position was the lowest in term PE compared to 41 
controls (p<0.032), similar to a South African cohort. Control but not all PE allele 42 
frequencies were in Hardy-Weinberg equilibrium (p=0.036). The Odds ratio for term PE 43 
calculated from prior risk, the A/A genotype and black ethnicity was 14 (p<0.001). In 44 
luciferase assays, the LGALS13 promoter “-98A" variant had 13% (p=0.04) and 26% 45 
(p<0.001) lower expression than the "-98C" variant in non-differentiated and 46 
differentiated BeWo cells, respectively. After 48-hour differentiation, there was 4.55- 47 
fold increase in expression of "-98C" variant versus 3.85-fold of "-98A" variant 48 
(p<0.001). 49 
CONCLUSION: Lower LGALS13 (PP13) expression by the "-98A/A" genotype 50 
appears to impose higher risk to develop PE and could aid in PE prediction. 51 
52 
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Introduction 53 
Preeclampsia (PE) is a pregnancy-specific disorder characterized by hypertension and 54 
proteinuria that occurs after 20 weeks of gestation [1,2]. According to the World 55 
Health Organization, PE is associated with significant maternal and perinatal 56 
mortality, and affects approximately 2-7% of all pregnant women [3]. Secondary PE 57 
symptoms include liver, kidneys, brain and the clotting system complication [4,5]. 58 
The disorder can exacerbate to stroke and convulsion (eclampsia) associated with 59 
severe morbidity and mortality [1-5].   60 
Epidemiological studies have indicated that PE has strong familial pre-disposition 61 
across ethnic groups, socio-economic, and geographic origins [6]. According to the 62 
South African (SA) Department of Health, the frequency of PE in 2015 was higher in 63 
SA than in England, particularly among the black and colored ethnic groups compared 64 
to the white ones [7]. At King’s College Hospital in London the incidence of PE is 65 
higher among black women attending prenatal screening and follow up compared to 66 
Caucasians [8]. According to Nakimuli et al. [6], there are different PE frequencies 67 
and sub-patterns between blacks from sub-Saharan or Caribbean origin in England 68 
and their counterparts of a Zulu origin in SA.  69 
Studies have implied an association between carriers of certain gene mutations 70 
and the development of PE [9]. Potential association of PE frequency was found 71 
among blacks and other ethnic groups of carriers of certain gene mutations, 72 
chromosomal changes and single nucleotide polymorphisms (SNPs). Such nucleic 73 
acid variations are particularly found in the context of blood pressure regulation [9], 74 
vasodilatation [10], angiogenesis regulation [11], and inflammatory genes, especially 75 
those encoding for interleukins [12]. Specific gene polymorphisms are involved in the 76 
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development of human placental diseases [13] but their role is not fully elucidated yet 77 
[14].  78 
Impaired placentation [15], loss of acquired maternal immunotolerance to the 79 
fetus [16], an intensified anti-angiogenic state [17], and inability of the cardiovascular 80 
system to adapt to the pregnancy burden [18-19] were listed among the leading causes 81 
that trigger PE. The search for genetic correlations has yielded examinations of 82 
polymorphisms among gene products that were implicated in the above functional 83 
pathways. One of them is Placental Protein 13 (PP13) and its encoding gene 84 
[LGALS13, NM_013268.2] [16, 20]. LGALS13 is located on chromosome 19q13 in 85 
close vicinity to additional genes of the galectin protein family [16, 20]. As a member 86 
of such galectin family, the protein product of LGALS13, PP13 has high affinity for 87 
sugar residues of glycoproteins, mainly annexin-II and actin- and - [16, 20-21]. 88 
PP13 is predominantly expressed at the outer layer of placental villi, on the apical 89 
brush border membrane of the syncytiotrophoblast facing maternal blood [16, 21-23]. 90 
The role of PP13 in the human placenta appears to be related to inflammation and 91 
immune defense [16, 23-24]. In recent years it was also discovered that when applied 92 
to gravid rodents PP13 decreases blood pressure and causes blood vessel expansion 93 
[25]. From the 5th week of pregnancy, PP13 can be identified in maternal blood, 94 
where its mRNA levels can also be determined [26-27]. A meta-analysis of 18 studies 95 
has reported reduced first trimester levels of PP13 protein and its respective mRNA in 96 
women developing PE later during pregnancy [22]. 97 
 The potential relations between the polymorphic variants of LGALS13 and the 98 
involvement of the encoded PP13 protein were first described by Bruins et al. [28], 99 
showing multiple SNP variants and emphasizing the importance of a particular one at 100 
the -98 position in the promoter region of LGALS13 [rs: 3764843]. They discovered 101 
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higher frequency of the A/A genotype versus A/C and C/C among women who 102 
developed term PE. Gebhardt et al. [14] have reported additional variants. They 103 
discovered a thymidine deletion at position 221 in exon three of LGALS13 (DelT221). 104 
Having the heterozygous deletion among black women in SA provided an 89% 105 
positive predictive value for the development of early-onset severe PE. Homozygous 106 
DelT221 variant was not associated with a viable pregnancy.  107 
The purpose of this study was to investigate polymorphisms in the LGALS13 108 
gene in a cohort enrolled for first trimester pregnancy evaluation at King’s College 109 
Hospital, London. Our aim was to compare LGALS13 polymorphisms in predicting 110 
PE. We also compared our data to the results published by the group from SA [14, 111 
28]. To evaluate the effect of this polymorphism on LGALS expression we have 112 
constructed LGALS13 promoter reporter clones with "A" or "C" in the -98 position 113 
and transfected them into BeWo human trophoblast-like cells. The expression was 114 
detected with the luciferase assays in order to assess the impact of the polymorphism 115 
on trophoblastic LGALS13 expression in vitro. 116 
 117 
118 
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Material and Methods 119 
Study population: 120 
We used a prospective cohort of women attending their routine first hospital visit at 121 
King's College Hospital, London, at gestational weeks 11+0 to 13+6 between March 122 
2006 and September 2009. The study was approved by the ethics committee of King's 123 
College Hospital. Women agreeing to participate provided written informed consent. 124 
Pregnancy age was determined by measurement of the fetal crown-rump length (CRL) 125 
[29]. 126 
We included pregnant women with viable singleton pregnancies who delivered 127 
live or a phenotypically normal stillbirth at or after 24 weeks of gestation. We 128 
excluded pregnancies with major fetal abnormalities and those ending in termination, 129 
miscarriage or fetal death before 24 weeks. 130 
Samples of serum and plasma were drawn in the first trimester and stored at - 131 
80°C for subsequent analysis. The samples were tested for a large diversity of 132 
biochemical markers as detailed by Akolekar et al. [8], including serum PP13. 133 
 134 
Maternal history and characteristics: 135 
Patients were asked to complete a questionnaire on maternal age, racial origin 136 
(Caucasian, African, South Asian, East Asian and mixed), method of conception 137 
(spontaneous or assisted conception requiring the use of ovulation drugs), cigarette 138 
smoking during pregnancy (yes/no), substance abuse during pregnancy (yes/no), 139 
history of chronic hypertension (yes/no), history of type 1 or 2 diabetes mellitus 140 
(yes/no), family history of PE in the mother of the patient (yes/no) and obstetric 141 
history including parity (parous/nulliparous if no previous pregnancies at or after 24 142 
weeks) and previous pregnancy with PE (yes/no). The questionnaire was then 143 
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reviewed by a doctor together with the patient, and maternal weight and height were 144 
measured [8]. Maternal mean arterial blood pressure (MAP) was measured by 145 
automated devices [30]. Trans-abdominal color Doppler ultrasound was used to 146 
visualize the left and right uterine artery and to measure the pulsatility index (PI) in 147 
each vessel and calculate the mean PI [31-32]. 148 
 149 
Outcome measures: 150 
The definition of PE was according to the International Society for the Study of 151 
Hypertension in Pregnancy [33]. The systolic blood pressure should be 140 mm Hg or 152 
more and/or the diastolic blood pressure should be 90 mm Hg or more on at least two 153 
occasions 4 h apart, developing after 20 weeks of gestation in previously 154 
normotensive women. There should also be proteinuria of 300 mg or more in 24 h or 155 
two readings of at least 2+ on dipstick analysis of midstream or catheter urine 156 
specimens, if no 24h urine collection is available. PE cases superimposed on chronic 157 
hypertension were excluded [33]. Data on pregnancy outcome were collected from the 158 
hospital maternity records or the women's general medical practitioners. The obstetric 159 
records of all women with hypertension were examined to differentiate between 160 
gestational hypertension and chronic hypertension. For this study we only used cases 161 
of term PE (n=49; delivery at >37 weeks) and preterm PE (n=18; delivery at 34-37 162 
weeks), but not early PE (delivery at <34 weeks) cases due to shortage of cases. 163 
 164 
Nested case-control study for biochemical markers: 165 
In the nested case-control study the cases were drawn from the study population as 166 
described above on the basis of availability of stored samples. The controls (n=196) 167 
were selected from pregnancies with no complications and normal outcome, and were 168 
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matched to the cases according to gestational week and storage time. None of the 169 
samples were previously thawed and refrozen.  170 
 171 
Serum PP13 testing: 172 
Serum PP13 was measured by DELFIA (Dissociation-Enhanced Lanthanide 173 
Fluorescent Immunoassay) using research reagents (PerkinElmer Life and Analytical 174 
Sciences, Turku, Finland) [8].  175 
 176 
Blood processing and DNA extraction: 177 
To study PP13 DNA polymorphisms, we used maternal plasma that was drawn from 178 
first trimester (gestational weeks 10-13) maternal peripheral veins and stored in 179 
ethylene-diamine-tetra-acetic acid (EDTA) tubes. Blood was centrifuged at 1,600 × g 180 
for 10 min at 4°C, and the supernatant plasma was aspired and re-centrifuged again at 181 
13,000 × g for 10 min at 4°C to remove residual cells. Cell-free DNA was extracted 182 
from 0.5 ml of plasma using AccuPrep Genomic DNA extraction kit (Bioneer 183 
Corporation, Daejeon, South Korea) according to the manufacturer’s instructions. 184 
DNA was eluted in 50µl double-distilled water (DDW). 185 
 We used Hylabs' recombinant clone that was constructed according to the 186 
website of the National Center for Biotechnology Information (NCBI) 187 
(http://www.ncbi.nlm.nih.gov/) to sequence the LGALS13 (NM 013268.2) gene. 188 
Primer pairs for PCR amplification were designed to encompass the promoter and 189 
intronic sequences flanking the PP13 encoding regions of each LGALS13 exon under 190 
investigation. 191 
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Primers were synthesized by the Hylabs' company oligo service unit using 192 
BH5 oligo making devise (Metabion, Planegg, Germany) and the Solid-Phase Oligo 193 
nucleotide Synthesis Method (ATDBio, University of South Hampton, the UK). 194 
Primer sequences are shown in Figure 1A and were verified by the Multiple 195 
Primer Analyzer (ThermoFisher, Waltham, MA USA) and sequence specificity using 196 
NCBI Basic Local Alignment Search Tool (http://www.ncbi.nlm.nih.gov/BLAST/). 197 
 198 
[Place here Fig 1: Primer details and PCR products ] 199 
 200 
PCR Reaction: 201 
PCR products were amplified according to LGALS13 exons and the flanking introns 202 
using Takara Ex Taq Hot Start kit (Cat. #R006A, Takara Bio, Kusatsu, Shiga, 203 
Japan). Each reaction was prepared to a final volume of 50µl containing 10µl of 204 
pregnant women’s plasma extracted genomic DNA (gDNA), and the Takara kit 205 
reagents including: 5µl of 10  Taq buffer, 4µl of dNTPs mixture (2.5 mM each), 1µl 206 
primer pairs at 10 mM concentration, 0.25µl of Taq DNA polymerase (5 U/µl) and 207 
30µl DDW. Amplifications were performed with the following sequential steps: 208 
denaturing at 98°C for 10 sec, followed by 40 cycles of amplification with initial 209 
denaturing at 94°C for 30 seconds, annealing of primers at corresponding temperature 210 
for 30 seconds and extension at 72°C for 60 seconds, and a final extension at 72°C for 211 
10 minutes. 212 
The PCR products (9 l each) were then mixed with 1 l of 10 loading buffer 213 
(Takara, Japan) and resolved by electrophoresis on 2% agarose gels in 1× TAE buffer 214 
(90 mM Tris–HCl, 90 mM boric acid and 1mM EDTA, pH 8.0) for 20 min to ensure a 215 
single PCR product (Figure 1B). The gels were then photographed under ultraviolet 216 
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light (260 nm) using a Bio-Rad Universal Hood and Bio-Rad Quantity One software 217 
(Bio-Rad, Hercules, CA, USA).  218 
Sequencing reactions were carried out using the BigDye® Terminator V1.1 219 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and the products 220 
were analyzed using an ABI 3730  l Genetic Analyzer (Applied Biosystems, USA). 221 
Sequencing was bi-directional to verify accuracy.  222 
Mutational analysis of the LGALS13 gene was performed using the BioEdit 223 
Sequence Alignment Editor version 7.2.5 (Isis Pharmaceutical, Carlsbad, CA, USA) 224 
(Figure 2A). SNPs were verified by repeating the sequence and PCR procedures 225 
(Figure 2B).  226 
 227 
[Place Here Figure 2: Sequencing of the -98 Promoter Region Site ] 228 
 229 
Transcription factor binding site analysis: 230 
The Transfac Database of the BIOBASE Biological Databases (www.biobase- 231 
international.com) was used to predict putative transcription factor binding sites in the 232 
promoter of LGALS13 gene. The Positional Probability Matrix (PPM) and the 233 
Positional Weight Matrix (PWM) of the canonical TFAP2A (transcription factor AP-2 234 
alpha, activating enhancer binding protein 2 alpha) binding site (MA0003.1) were 235 
downloaded from the Jaspar database (http://jaspar.genereg.net/). 236 
 237 
Promoter luciferase assays: 238 
To test the effect of the A/C variation in -98 position of the LGALS13 promoter on 239 
gene expression, luciferase assays coupled with trophoblast differentiation 240 
experiments were completed following published protocols [34]. Briefly, the 241 
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LGALS13 promoter reporter construct, which contains Gaussia luciferase reporter 242 
gene linked to the LGALS13 promoter, was designed at the NIH Perinatology 243 
Research Branch and generated by GeneCopoeia (Rockville, MD, USA). This “-98C” 244 
clone contains a cytosine in the -98 position. An additional reporter construct (“- 245 
98A”) was generated at the Hungarian Academy of Sciences Research Centre for 246 
Natural Sciences by replacing cytosine for adenine in -98 position by site directed 247 
mutagenesis using the QuikChange Lightning kit (Agilent Technologies, Santa Clara, 248 
CA, USA) following the manufacturer´s protocol.  249 
The "98C“ and "-98A“ reporter constructs (1 g/well in a 24-well plate) were 250 
transfected into BeWo cells (American Type Culture Collection, Manassas, VA, 251 
USA) cultured in F12K medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented 252 
with 10% fetal bovine serum (Gibco-ThermoFisher Scientific, Waltham, MA, USA) 253 
using Lipofectamine-2000 reagent (Invitrogen-ThermoFisher Scientific) according to 254 
the manufacturer´s protocol. Twenty four hours after transfection, BeWo cells were 255 
treated with either Forskolin (25 µM in DMSO; Sigma-Aldrich) or DMSO, and 256 
incubated at 37°C for 48h. In all experiments, supernatants were collected and 257 
secreted Gaussia luciferase activity was determined by Secrete-Pair Gaussia 258 
Luciferase Assay (Genecopoeia) according to the manufacturer’s protocol. This assay 259 
measured the Gaussia luciferase reporter gene's expression linked to the LGALS13 260 
promoter by measuring the luciferase activity of the secreted luciferase reporter 261 
protein, since secreted luciferase activity correlates with LGALS13 promoter activity 262 
and luciferase gene expression. The luminescence was immediately measured with a 263 
Victor X3 microplate reader (PerkinElmer, Inc., Waltham, MA, USA).  264 
265 
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Statistical analysis: 266 
General - For categorical variables comparisons between each outcome group and 267 
unaffected controls were made by Fisher’s exact test. Kruskal-Wallis or Mann 268 
Whitney non-parametric tests were used for continuous variables.  269 
Hardy-Weinberg equilibrium and 2 tests were used to compare the genotype 270 
and allelic frequency distribution in the study groups. Genotypes and alleles were 271 
considered to be in Hardy-Weinberg equilibrium if the observed frequencies did not 272 
differ significantly from the expected (p>0.05). The 95% confidence intervals (CI) 273 
were determined to verify the pattern of population distribution and overlap. 274 
Luciferase assays - Data generated by luciferase assays were analyzed using 275 
the t-test for comparison between the constructs.  276 
P-values of 5% or less were considered as significantly different. The data 277 
were analyzed using the SPSS version 24 (SPSS Inc., Chicago, IL, USA). 278 
Odds Ratios (OR) for individual maternal risk to develop PE were calculated 279 
first on their own ad then adjusted given having the other ones. Multiple regression 280 
was then calculated according to all adjusted risk factors from the observed measures.  281 
Likelihood ratio (LR)- Positive LR was calculated according to [sensitivity/(1- 282 
specificity)] and negative LR was calculated according to: [(1-sensitivity/Specificity]. 283 
Overall LR was the division of the positive and the negative LR.  284 
Power analysis was conducted assuming the detection accuracy of promoter 285 
genotype polymorphism is 100%. Accordingly, we evaluated the frequency of the "A" 286 
allele in the control and PE groups. To yield the power of the study given 5% type 1 287 
erro we  entered these values into the PS Power and Sample Size Program (version 288 
3.1.2) (http://ps-power-and-sample-size-calculation.software.informer.com)  289 
 290 
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Results 291 
We have identified 20 preterm PE cases (delivered at gestational age between 34 to 36 292 
weeks and 6 days) and 50 cases of late PE (delivery >37 weeks). These were matched 293 
to 200 unaffected controls, according to the time of enrolment (+ 1 week) and 294 
gestational age at enrolment (+ 1 week). The amount of cell-free DNA extracted from 295 
the samples was sufficient to run the analysis for 196 controls, 18 preterm PE cases 296 
and 49 term PE cases. In case of other samples, we could not isolate a suitable amount 297 
of cell-free DNA to conduct the analysis.  298 
Cases and controls' demographic and pregnancy information are summarized 299 
in Table 1, showing that gestational week (CRL) at enrolment were not different 300 
between the groups. Cases that developed PE had higher maternal body mass index 301 
(BMI) at enrolment, and lower frequency of spontaneous conception (e.g. – more 302 
conceived by assisted reproduction technology (ART). In the PE group, there were 303 
more women with a history of previous PE and black ethnicity.  304 
 305 
[Place here Table 1. Enrolment and delivery information in pregnancies with 306 
and without PE]. 307 
 308 
The PP13 serum level: 309 
The PP13 serum level was previously reported by Akolekar et al. [8]. Accordingly, 310 
the PP13 first trimester level expressed as multiple of the median in un-affected 311 
patients was 1.00 [0.76-1.33] [median and 95% CI], compared to 0.93 [0.7-1.3] and 312 
1.11 [0.89-1.49] for preterm PE and term PE, respectively. The detection rate for 10% 313 
false positive rate was 41.4 [32.2-51.2] and 37.8 [28.9-47.6] for preterm PE and term 314 
PE, respectively.  315 
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Combining maternal prior risk factors, biochemical and biophysical markers 316 
the prediction of PE was 79.5% and 64.2% for preterm PE and term PE, respectively. 317 
Adding PP13 to the prediction of PE increased the prediction accuracy to 85.9% and 318 
71.2%, respectively.  319 
 320 
Polymorphisms: 321 
As depicted in Table 2, the respective primers revealed the presence of several of the 322 
previously reported polymorphic variants reported by Gebhardt et al. [14] and a few 323 
new ones, not previously listed in the NCBI SNP database of LGALS13. In this 324 
cohort, the DelT221 variant of Gebhardt et al. [14] was not found. This is most likely 325 
related to the relative small study size.  For o,8 power, a 1:4 ratio of cases and 326 
controls, a sample size of 168 cases of early severe PE versus 672 controls is required 327 
to identify the DelT221 mutation. Such large number of early cases is not available to 328 
us today. 329 
There were additional SNPs that were reported in SA and not found in the 330 
London cohort (Table 2). Those that were detected (new and old ones) did not appear 331 
in a significant number of samples to run analysis for elucidating any specific 332 
conjunction with PE except -98A/C [28]. 333 
 334 
[Place here Table 2. SNP variants identified in the LGALS13 gene.] 335 
 336 
-98A/C genotype variation (dbSNP: rs3764843): 337 
The -98 A/C genotype polymorphism was detected using the pair of the first two 338 
primers (Figs. 2 A and B). Table 3 depicts the genotype distribution in PE and 339 
unaffected controls. The A/A variant at the -98 position [28] was found to be the 340 
dominant genotype in all groups. The C/C genotype has the lowest frequency. In the 341 
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comparison between groups, the frequency of the A/C genotype was higher in term 342 
PE, less in preterm PE, and the lowest in the unaffected group.  343 
The pattern of genotype distribution was more significantly different when 344 
comparing term PE cases to controls (p=0.032) than when all PE cases were 345 
compared to controls (p=0.068). There was no difference (p=0.730) in genotype 346 
pattern distribution for preterm PE compared to controls (Table 3), presumably due to 347 
the very low number of preterm PE cases.  348 
 349 
[Place here Table 3. Correlation between patient outcome groups and genotype.] 350 
 351 
Altogether, our sample had  controls to 1 term PE case . Thus, among the 196 352 
unaffecred controls the "A" allele appears 312 times, corresponding a probability of 353 
0.8. Among the 49 term PE cases the "A" allele appears 80 times, corresponding to 354 
probability of 0.92 . Accordingly, the study power for this polymorphism was 0.9 355 
given =0.05. The sample size of preterm PE was underpower for an accurate 356 
probability assessment in this study. 357 
Cohort comparison between London and South Africa (SA): 358 
• A/A genotype - In both the SA and the London cohorts the A/A genotype 359 
had a higher allele frequency overall. However, the A/A majority was more 360 
dominant for PE cases compared to control in both London and SA 361 
(p<0.001) (Table 4). For the A/A genotype, the odds ratio for term PE was 362 
OR=2.91 in London and OR=1.84 for the SA population.  363 
• A/C genotype - The A/C genotype was higher in controls than in PE in both 364 
SA and London cohorts.  365 
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• C/C genotype - The C/C genotype was carried by too few subjects and thus 366 
statistical evaluation was not valuable. 367 
 368 
[Place here Table 4. 2 for good of fit to measure the distribution of the genotype 369 
in London and SA by outcome]. 370 
 371 
 In summary, while there were some differences in the genotype distributions 372 
between SA and London, the presence of cytosine nucleotide in -98 promoter position 373 
(either as a heterozygous (A/C) or homozygous (C/C) genotype) was higher in 374 
unaffected controls versus all PE cases and particularly in term PE cases (p<0.001). 375 
 The comparison of genotype distribution according to racial origin is depicted in 376 
Table 5. For the population at large, both black and non-black had a higher frequency 377 
of the A/A genotype and a lower frequency of the A/C and C/C genotypes (p=0.813). 378 
However, there was significant correlation between black ethnicity and PE. Term PE 379 
was more frequent in black compared to the non-blacks (31.5% vs. 12.1%, p<0.001). 380 
 381 
[Place Table 5. Correlation between patient's race and genotype or patient race 382 
and outcome.] 383 
 384 
Genotype, ethnicity and outcome: 385 
The C allele (in either C/C or A/C genotype) appears to confer protection from 386 
developing term PE for all ethnic groups (Table 6). The A/A genotype was more 387 
common in black women with term PE. Accordingly, there was high correlation 388 
between term PE outcome, A/A genotype and black ethnicity.  389 
 390 
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[Place here Table 6. Correlations between patient's genotype and race according 391 
to the outcome group].  392 
 393 
Hardy-Weinberg analysis: 394 
Applying the Hardy-Weinberg equation to the genotype distribution as summarized in 395 
Table 3 yielded the followings: 396 
• The A/A genotype was detected in 82.1% of cases and 67.3% of controls.  397 
• Heterozygosity (A/C) was detected in 13.4% of cases and 24.5% of controls.  398 
• The C/C genotype was detected in 4.5% of the cases and 8.2% of controls.  399 
Accordingly, the genotype frequencies in the control individuals were in Hardy- 400 
Weinberg equilibrium. However, All PE cases deviated significantly from equilibrium 401 
(p=0.036).  402 
 403 
 404 
Odds ratios: 405 
Calculation of the OR based on a recessive homozygosity model for PE development 406 
was conducted by comparing the A/A genotypes to other genotypes. It yielded an 407 
OR=1.26 for preterm PE, OR=2.91 for term PE and OR=2.22 for all PE (values not 408 
shown). This was consistent with the previous report from SA [28] that the to be 409 
protective against PE development. However, on its own the promoter variant 410 
genotypes were not strong enough as stand-alone markers for predicting PE.  411 
A Multi-Variate analysis was conducted including: having A/A genotype in -98 412 
position, being of black ethnicity and experiencing previous PE as major confounders, 413 
and high body mass index (BMI) and maternal age as weaker contributors. The 414 
individual odds ratios (ORs) for developing PE were then recalculated to account for 415 
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each risk factor considering the presence of the other risk factors to yield the adjusted 416 
OR (Table 7).  417 
 418 
[Place here Table 7. Genotype and other risk factors – adjusted odds ratios.] 419 
 420 
• The accuracy of the observed overall multiple marker assessment was 77.9% for 421 
all PE and 83.7% for term PE and 6% and 3% false positive rates, respectively.  422 
• The combined OR for All PE had R2=0,24, χ2(5)= 47.35, p<0.001, and an Adjusted 423 
OR=7.  424 
• Combined OR for term PE has R2=0.27, χ2(5)=44.99, p<0.001 and the adjusted 425 
OR=14  426 
• The Positive Likelihood ratio (LR)=[Sensitivity/(1-Specificity)] was 10.2 and 5.21 427 
for term PE and All PE, respectively.  428 
• The Negative LR-[(1-sensitivity)/ Specificity] was 0.72 and O.73 for term PE and 429 
All PE, respectively.  430 
• The Overall LR=Positive LR/Negative LR were 14.17 and 7.13 for term PE and 431 
All PE, respectively. 432 
 433 
The effect of -98 polymorphism on LGALS13 expression: 434 
In order to study the functional effect of this polymorphism, first we performed a 435 
transcription factor binding site search using the Transfac database, which revealed a 436 
TFAP2A binding site in the LGALS13 gene promoter at -101 to -93 positions (Figure 437 
3A). Of interest, the comparison of this binding site nucleotide sequence with the 438 
PPM and PWM of the canonical TFAP2A binding site (MA0003.1) in the Jaspar 439 
database showed that: 1) 7 out of the 9 bases in the LGALS13 promoter binding site 440 
match the most frequent bases in the canonical binding site; and 2) the „C” in -98 441 
position has a higher occurrence, and thus binding affinity, than “A” in the canonical 442 
binding site (Figure 3B). This suggested that having “A” in -98 position may lead to 443 
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weaker binding of TFAP2A than having “C” in the same position in the LGALS13 444 
promoter and a consequent lower LGALS13 gene expression.  445 
 446 
[Place here Figure 3: Promoter luciferase assays] 447 
 448 
To investigate this hypothesis, next we generated “-98C” and “-98A” 449 
LGALS13 promoter clones and examined their expression in non-differentiated and 450 
differentiated BeWo cells. BeWo cells have TFAP2A expression in the non- 451 
differentiated state, which increases during trophoblast differentiation. Therefore, we 452 
expected to find an increasing difference in luciferase activity with the progress of 453 
differentiation between the two clones. Indeed, promoter “-98A" variant had 13% 454 
lower expression in non-differentiated BeWo cells (p=0.04) while it had 26% lower 455 
expression in Forskolin-induced BeWo cells after 48 hours of differentiation 456 
(p<0.001) compared to the "-98C" variant. The expression of both promoter variants 457 
increased during the 48 hours of differentiation. However, the increased expression of 458 
"-98C" variant was by 4.55-fold while the increased expression of "-98A" variant was 459 
only by 3.85-fold increase (-15%, p<0.001). 460 
 461 
462 
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Discussion  463 
Major findings of the study: 464 
1)  LGALS13 -98 A/C genotype was the lowest in term PE compared to controls 465 
(p<0.032), similar to a South African cohort; 2) Control but not all PE allele 466 
frequencies were in Hardy-Weinberg equilibrium (p=0.036); 3) The Odds ratio for 467 
term PE calculated from prior risk, the A/A genotype and black ethnicity was 14 468 
(p<0.001); 4) In luciferase assays, the LGALS13 promoter “-98A" variant had 13% 469 
(p=0.04) and 26% (p<0.001) lower expression than the "-98C" variant in non- 470 
differentiated and differentiated BeWo cells, respectively. After 48 hours of 471 
differentiation, there was 4.55-fold increase in expression of "-98C" variant versus 472 
3.85-fold of "-98A" variant (p<0.001). 473 
 474 
The relevance of -98A/C LGALS13 polymorphism for preeclampsia prediction 475 
In the present study, we searched for first trimester SNPs of the LGALS13 gene 476 
encoding for PP13 and the potential relevance of these SNPs to PE prediction. An 477 
A/C polymorphism previously reported for the -98 promoter position of LGALS13 478 
gene in a SA cohort collected at term. Our study revealed it for a cohort from London 479 
already in the first trimester samples.  480 
 The presence of cytosine ("C") in the -98 position (either in its heterozygous 481 
A/C genotype variant or the homozygous C/C variant) seems to convey protection 482 
from the development of PE, as was previously reported for the cohort in SA [28]. 483 
This protection from PE is probably related to the higher expression of LGALS13 484 
when "C" is in the -98 position compared to "A" in this position in the LGALS13 485 
promoter, as was detected in BeWo trophoblast-like cells. Our study revealed that 486 
while the unaffected control group was in Hardy-Weinberg equilibrium, all PE cases 487 
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deviated from it. This was true for both the London and the SA cohorts, and strongly 488 
emphasized that having the "C" variant in the -98 position is protecting from 489 
developing PE.  490 
PP13 was implicated in several functions of placental development, including 491 
immune tolerance to the paternal genes of the migrating trophoblasts [16, 23] as well 492 
as blood pressure and utero-placental vasculature control [25]. Therefore, knowledge 493 
of polymorphisms in the promoter for this gene might facilitate our understanding of 494 
its potential role in regulating the normal progress of pregnancy. The presence of 495 
cytosine either in the C/C or A/C format appeared to convey protection from PE, 496 
regardless of the differences in the genotype distributions between SA and London.  497 
We have found that genotype variation in the -98 position and black ethnic 498 
origin were major contributors in predicting high risk to develop PE. Some 499 
differences were found between the London and the SA cohorts in the proportion of 500 
A/A, C/C and A/C. Regardless of those differences, in both cohorts having the "C" 501 
variant was protecting from PE. The differences  in the distributions may be related to 502 
tribe origin: Sub-Saharan and Caribbean origin in London compared to Zulu and 503 
additional South- and Central African origin in SA [8, 15]. In this context on may 504 
address the issue of ancestry information markers (AIMS). To the best of our 505 
knowledge there are no AIMS for preeclampsia that can be used in PE predicting 506 
according to ethnic origin, although such AIMS were described for certain different 507 
geographical regions in the context of other diseases [6-7]. Given the different 508 
frequency of PE even among the black ethnic group between South African, 509 
Caribbean African and African-American, in the future the polymorphism of PP13 510 
may be developed as a potential future AIM for preeclampsia. 511 
 512 
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The relevance of -98A/C polymorphism for LGALS13 expression 513 
How the cytosine nucleotide in the A/C or C/C configuration (versus A/A genotype) 514 
in -98 position in the promoter region of LGALS13 may convey resistance to PE? The 515 
transcription factor binding site analysis has indicated that having “C” in -98 position 516 
in the LGALS13 promoter compared to having “A” in this position predicts a higher 517 
binding of TFAP2A. This transcription factor is critical for the trophoblastic 518 
expression of several placental genes including LGALS13 and other galectin genes in 519 
its close vicinity on Chr19 [34]. Thus, it was anticipated that having “C” in the -98 520 
position yields a higher LGALS13 gene expression and consequently more PP13 521 
protein synthesis.  522 
Indeed, the in vitro expression studies confirmed this in silico analysis. We 523 
performed luciferase assays on the "-98C" and the "-98A" LGALS13 promoter clones. 524 
It was found that the "98A" variant had lower expression in both non-differentiated 525 
and differentiated BeWo cells compared to the "-98C" variant. In addition, during 526 
differentiation, having the "-98C" variant in the promoter construct was accompanied 527 
by a higher fold increase of expression compared to having the "-98A. Since 528 
luciferase assays measured only the expression of the promoter constructs transfected 529 
into BeWo cells but not the internal expression of LGALS13 gene copies in BeWo 530 
cells, the genotype of BeWo cells for the -98A/C LGALS13 polymorhisms as well as 531 
their aneuploidity [35] did not interfere with our assay.  532 
The expression studies with the -98 "A" and "C" promoter reporter variants 533 
emphasized the effect of this polymorphism on LGALS13 expression in the context of 534 
trophoblast differentiation. It is important, since there is an elevated induction of 535 
LGALS13 expression during the differentiation of the trophoblasts to generate the 536 
placental villi, in correlation with the increased expression of TFAP2A among other 537 
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transcription regulatory genes [34]. Thus, this functional observation validates in the 538 
in-silico prediction of the role of TFAP2A binding to the polymorphism containing 539 
binding site. Moreover, Kliman et al. [23] have shown that PP13 is involved in the 540 
remodeling of the utero-placental vasculature. Furthermore, both Kliman et al [23] 541 
and Then et al. [16] have shown that PP13 induces white blood cell apoptosis and 542 
confers maternal immunotolerance to the pregnancies. Thus, the results of this study 543 
point to the potential link between placental development, trophoblast differentiation, 544 
LGALS13 expression, maternal blood PP13 concentrations and normal pregnancy 545 
maintenance, and prompts additional studies – functional and clinical - to uncover this 546 
unexplored area in details.  547 
 548 
The relevance of LGALS13 polymorphisms for the development of preeclampsia 549 
We determined LGALS13 on cell free DNA of maternal blood. In recent years, several 550 
tools were developed to investigate how impairments in LGALS13 nucleotide 551 
sequence and its RNA/protein expression could affect the risk to develop PE [14, 22, 552 
24, 28, 36]. In addition to the - 98A/C promoter polymorphism, there is an additional 553 
polymorphism of having deletion of the nucleotide thymidine in position 221 554 
(DelT221). Identified among black women in SA by Gebhardt et al. [14], the DelT221 555 
variant conveyed an 89% positive predictive value for developing early-onset severe 556 
PE when present in its heterozygous form. The homozygous form was not associated 557 
with viable pregnancy. Sammar et al. [37] constructed the DelT221 variant and 558 
expressed both the wild type and the DelT221 variants of LGALS13 in E. coli. The 559 
polypeptides were subsequently purified as recombinant proteins. The DelT221 variant 560 
is a shorter polypeptide caused by a premature stop codon in the open reading frame 561 
compared to the wild type PP13. This wild type PP13 and its truncated PP13 variant 562 
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were both found to reduce blood pressure when applied to gravid rats, and this effect 563 
lasted for the entire period of PP13 delivery from a slow releasing inter peritoneal 564 
pump application [25]. However, unlike the wild-type, the truncated protein failed to 565 
cause expansion of the utero-placental vasculature and could not increase placental 566 
size and pup weight [25, 37]. These findings emphasize the role of the sugar binding 567 
residues of PP13 molecule that are partially missing in the truncated variant as was 568 
demonstrated previously [16, 34, 36]. However, as indicated above, the sample size of 569 
early severe PE cases and overall in this study was too small to identify the DelT221 570 
mutation. 571 
The very rare DelT221 mutation and the -98A/C polymorphism demonstrate  572 
the importance of PP13 in PE research. In the case of the DelT221 mutation, a strong 573 
risk to develop early onset and severe PE was discovered [14]. In the case of the -98 574 
A/C promoter variants, the impact is increased risk to develop term and all cases of 575 
PE. Accordingly, each variant conveyed a different risk level to develop PE. Further 576 
studies in PE and animal models may reveal the physiological and morphological 577 
mediators involved in the risk to develop PE derived from each variant and for the 578 
two combined.  579 
 580 
The relevance of gene polymorphisms for the development of preeclampsia 581 
Preeclampsia is a multifactorial disorder. Our study emphasized the increase in our 582 
tool box for identifying patients at risk to develop PE, which may be derived from 583 
impaired sequence and/or expression of LGALS13 gene and the encoded PP13 584 
protein. Increasing this tool box may improve our ability to develop novel drug-target 585 
composite through identifying the sub-group of patients whose risk to develop PE is 586 
associated with impaired PP13 sequence / expression / function. PE research signals 587 
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the need to link marker discovery, risk stratification, and identify subgroup candidates 588 
for evaluating potential new methods of therapy. This approach may open the road to 589 
facilitate the delivery of new monitoring and management [38].  590 
Polymorphisms were already identified in various genes of proteins that are 591 
involved in different functions related to the PE disorder [9-14]. Among them are the 592 
polymorphisms in genes that are involved in blood pressure regulation through the 593 
renin-angiotensin-aldosterone system. Polymorphisms in this system are associated 594 
with hypertensive disorders in pregnancy as was reported for the white population of 595 
Poland [39], and the black Afro-Caribbean, but not the white Europeans in South and 596 
Central London [9]. However, this was not the case among Asian women of Taiwan 597 
[9]. More than one type of polymorphism in this system, including the variant related 598 
to hypertensive disorders in pregnancy, was identified among Tunisian Arabs [40]. At 599 
the same time, these two variants of polymorphisms have been shown to be tightly 600 
related to other cardiovascular disorders. The latter includes congestive 601 
cardiomyopathy, supraventricular arrhythmias, reduced exercise capacity and an 602 
increase in left ventricular systolic dimension. They all underline the higher frequency 603 
of cardiovascular morbidity among women who experience hypertensive disorders in 604 
pregnancy [41-42].  605 
Polymorphisms were also identified in the endothelial nitric oxide synthase 606 
(eNOS) system that regulates vasodilation, which is one of the hallmarks of early 607 
stages of pregnancy development. Linkage studies in affected sibling pairs have 608 
implicated the NOS3 gene (encoding eNOS) locus on chromosome 7q35 [10, 43]. 609 
However, a recent meta-analysis failed to show a repeated correlation between this 610 
polymorphism and PE, either because the studies were not powered or because this 611 
candidate gene might be different according to ethnic background [9-10]. 612 
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Analysis of the polymorphisms of IL27 in PE among Han Chinese women 613 
revealed a significantly reduced risk of PE in one genotype variant compared to the 614 
others in a dominant allele model. This was particularly true for the severe PE 615 
subgroup, implying that SNPs in IL27 may have an effect on individual susceptibility 616 
to PE [12].  617 
These findings may lead to the development of new tools for PE prediction 618 
based on SNPs. A new diagnostic approach can be adapted based on the use of a 619 
battery of several SNPs. Tools like quantitative real time multiplex PCR or DNA 620 
chips could be developed to identify pre-dispositions to develop PE.  621 
PE has a significant inherited component and it is likely that many genes are 622 
involved [44]. Considering that the etiology of PE remains complex, identification of 623 
candidate genes for PE pre-disposition could be a substantial aid in the understanding 624 
of this important public health problem and provide clues for prevention and 625 
treatment. It might also have wide relevance since women with a history of PE are at 626 
increased risk of cardiovascular disease in later life [45].  627 
 628 
Study Limitation 629 
While our study was powered enough to predict term PE according to -98A/C 630 
polymorphism, the study was underpowered to evaluate the value of this 631 
polymorphism for predicted preterm PE. This is only the second study that explore the 632 
polymorphism of PP13 following a previous one conducted in South Africa [28]. 633 
While both studies implies the importance of PP13 promotor -98 A/C polymorphism, 634 
more studies are required with additional cohorts of other ethnic origins to verify the 635 
use of this polymorphism in predicting PE. For identifying carriers of the delT221 636 
much larger sample size is required in view of the rare mutation frequency. 637 
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 638 
Is the LGALS13 DNA detected here in this study of maternal or fetal origin?  639 
Studies have shown that approximately 5-10% of the cell-free DNA in first 640 
trimester maternal blood is of fetal/placental origin while 90-95% is of maternal 641 
origin [46]. Therefore, 90-95% of cell-free genomic DNA fragments carrying the 642 
LGALS13 gene are supposed to be originated from maternal tissues. Since LGALS13 643 
is 5,000 base-pairs long compared to the 3 billion base-pair length of the human 644 
genome, the isolated cell-free genomic DNA contained approximately 1.7x10-4 % of 645 
maternal and fetal LGALS13 sequences combined and 1.7x10-5 % of fetal LGALS13 646 
sequences. Accordingly, we estimate that the fetal fraction of LGALS13 in this study 647 
was too low for detection.  648 
Conclusion  649 
This is the first study conducted to identify LGALS13 DNA sequence variants in 650 
maternal blood in the first trimester. Our findings suggest that the -98A/C gene 651 
polymorphisms in the promoter region of the LGALS13 gene may be associated with 652 
PE development with strong correlation to black ethnicity. The -98 A/C genotype 653 
appears to provide protection from PE development. More studies are required to 654 
verify the use of the -98A/C promoter variant for aiding PE prediction alone or in 655 
combination with genetic variants of other genes with possible diagnostic significance 656 
[47-49]. Further studies are required in PE models to examine the impact of the 657 
polymorphism on the disease development and in finding novel therapies. 658 
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Tables 837 
 838 
Table 1. Enrolment and delivery information in pregnancies with and without 839 
PE. 840 
  841 
Parameter Controls 
(n=196) 
Term PE 
(n=49) 
Preterm PE 
(18) 
p 
Enrolment     
BMI (kg/h2) 
(Mean [95% CI])  
25.2b [24.5-25.9] 29.5a [27.5-31.5] 29.9a [26.7-33.1] <0.001 
Maternal age (yrs) 
(Mean [95% CI]) 
31.9 [31.0-32.7] 31.0 [29.4-32.5] 33.2 [29.6-36.7] 0.178 
Smoking (%) 7.7 6.1 0.0 0.479 
Conception  
Spontaneous (%) 
95.9 95.9 88.9 0.415 
Previous PE or GH 
(%) 
4.6b 20.4a 16.7 a 0.002 
Ethnicity Black (%) 27.6b 57.1a 38.9a <0.001 
Delivery     
Gestation age (days) 
(mean [95% CI])  
39.9a [39.7-40.1] 39.3a [38.9-39.6] 35.8b [35.4-36.2] <0.001 
Baby weight (gr) 
(Mean[95% CI])  
3399a [3352-3447] 3145b [3010-3281] 2244c [2054-2435] <0.001 
 842 
PE - pre-eclampsia, GH - gestational hypertension, BMI - body mass index 843 
The letter indicate significantly higher (a),  lower (b) or the lowest (c) 844 
 845 
846 
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Table 2. SNP variants identified in the LGALS13 gene. 847 
 848 
Variant name Code Region a.a substitution 
No. of 
individuals 
-98 A/C rs 3764843 Promoter -  244 
15 C to T Novel Exon 1 P -> P 1 
Ex1+104 C/T rs 3764844 Intron 1 - 6 
Ex1+116 C/T Novel Intron 1 - 13 
Ex3-15 G/A rs 116537355 Intron 2 - 2 
Ex3-22 A/G rs 2233706 Intron 2 - 14 
Ex3-36 A/G rs 201378711 Intron 2 - 0 
130 A to G rs 774287801 Exon3 M -> V 0 
221delT rs 371049824 Exon 3 - 0 
229-237HotSpot - Exon 3 T->N, T->L, D->H 0 
260 A to G rs 74400185 Exon3 K -> R 0 
330 C to T Novel Exon 4  Y -> Y 1 
The list of variant names includes all those already listed by Gebhardt et al. [14] for 849 
the SA cohort, even if not found here and the three novel variants discovered for the 850 
London cohort and not yet included in the NCBI library.  851 
1. Novel Exonic variant 15 C to T (30 nucleotides before and after)  852 
CAAGAAGGAGAGAACAATGTCTTCTTTACC[C/T] 853 
GTGAGTTGAAAAGGCACAGCCTTCAAAAAT 854 
2. Novel Intronic variant EX1+116 (30 nucleotides before and after)  855 
GCATTTTTGCTGTGAATGCTTTACTTAGAG[C/T] 856 
TATTGAGGTGTGGAATAGAAACCCTGAGGC 857 
3.  Novel Exonic 330 C to T (30 nucleotides before and after)  858 
GTAGATAAAGGTCAATGGCATACGCATTTA[C/T] 859 
GGCTTTGTCCATCGAATCCCGCCATCATTT 860 
861 
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Table 3. Correlation between patient outcome groups and genotype. 862 
 
Unaffected 
Control 
(n=196) 
All 
PE 
(n=67) 
Preterm PE 
(PE 34+0 - 36+6) 
(n=18) 
Term PE 
(PE>37 weeks 
(n=49) 
Genotype N % N % N % N % 
A/A 132 67.3 55 82.1 13 72.2 42 85.5 
A/C 48 24.5 9 13.4 3 16.7 6 12.2 
C/C 16 8.2 3 4.5 2 11.1 1 2 
p   p=0.068 p=0.730 p=0.032 
 863 
LGALS13 gene was sequenced from maternal plasma cfDNA of PE and non-PE using 864 
the primers flanking exon 1 and the flanking introns. 865 
 866 
 867 
868 
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Table 4. 2 for good of fit to measure the distribution of the genotype in London 869 
and SA by outcome. 870 
 871 
 
Genotype 
Control 
London 
N=196 
Control 
SA 
N=282 
Term 
PE London 
N=49 
Term 
PE SA 
N=34 
N % N % N % N % 
A/A 132 67.3 150 53.0 42 85.8 23 67.7 
A/C 48 24.5 114 40.5 6 12.2 6 17.6 
C/C 16 8.2 18 6.5 1 2.0 5 14.7 
p p<0.001 p=0.014 
 872 
The results of SA were extracted from Bruiners et al. [28]. 873 
The statistical significance compared the patients according to the outcome group 874 
 875 
876 
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Table 5. Correlation between patient's race and genotype or patient race and 877 
outcome. 878 
 
 
Genotype 
Black 
(n=89) 
Non Black 
(n=140) 
 
N % N %  
A/A 63 70.8 101 72.2  
p=0.813 
 
A/C 19 21.3 31 22.1 
C/C 7 7.9 8 5.7 
Group 
Control 54 60.7 114 81.5  
p<0.001 Preterm PE 7 7.9 9 6.4 
Term PE 28 31.5 17 12.1 
Top: Genotype distribution according to ethnic origin.  Comparison was made 879 
between black and non-black according to having the detected all three genotypes and 880 
not for comparing each genotype on its own, and indicated no significance difference 881 
in the genotype distribution.  882 
Bottom: Outcome distribution according to ethnic origin.  Comparison was 883 
made between black and non-black according to the distribution of all three outcome 884 
groups (and not for comparing each outcome group on its own), and indicated 885 
significant higher frequency of PE in the black ethnic group.  886 
 887 
888 
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Table 6. Correlations between patient's genotype and race according to the 889 
outcome group. 890 
 
Control 
Black (n=54) Non Black (n=114) 
 
N % N % 
A/A 35 64.8 79 69.3 
p=0.527 A/C 13 24.1 28 24.6 
C/C 6 11.1 7 6.1 
Preterm PE 
Genotype 
Black (n=7) Non Black (n=9)  
 
 
p=0.213 
N % N % 
A/A 6 85.7 6 66.7 
A/C 0 0 3 33.3 
C/C 1 14.3 0 0 
Term PE 
Genotype 
Black (n=28) Non Black (n=17) 
 
 
p=0.043 
N % N % 
A/A 22 78.6 16 94.1 
A/C 6 21.4 0 0 
C/C 0 0 1 5.9 
Top: Genotype distribution in the control outcome according to ethnicity showed no 891 
significant difference of the three genotypes according to ethnicity. 892 
Middle: Genotype distribution in the preterm PE according to ethnicity showed no 893 
significant difference of the three genotypes according to ethnicity 894 
Bottom: Genotype distribution in the term PE outcome according to ethnicity showed  895 
significant difference of the three genotypes according to ethnicity 896 
 897 
 898 
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Table 7. Genotype and other risk factors – adjusted odds ratios. 900 
 All PE Term PE 
Parameter OR [95% CI] p OR [(95% CI] p 
A/A genotype 2.57 [1.18-5.61] 0.018 3.68 [1.34-9.72] 0.009 
Black Ethnicity 1.97 [1.03-3.77] 0.039 2.40 [1.16-4.97] 0.018 
BMI (kg/h2) 1.12 [1.06-1.19] <0.001 1.12 [1.05-1.19] <0.001 
Previous PE 3.79 [1.44-10.00] 0.007 4.67 [1.63-13.37] 0.004 
Maternal age (years) 0.98 [0.93-1.03] 0.410 0.96 [0.90-1.02] 0.194 
Overall accuracy (%) 77.9 83.7 
Overall OR 7.0 14.0 
Detection Rate (%) 31.3 30.6 
False Positive Rate (%) 6 3 
Positive LR 5.21 10.2 
Negative LR 0.73 0.72 
Overall LR 7.13 14.17 
 901 
Top: Assessments of the adjusted Odds ratios (OR) based on the calculation of the 902 
individual confounder OR given the other confounders. The followings confounders 903 
showed significant differences: A/A genotype, previous PE, black ethnicity, BMI and 904 
maternal age.  905 
Multiple regression was conducted for all these adjusted values combined. Detection 906 
rate and false positive rates were calculated from the observed measures. Positive, 907 
Negative and overall LR were calculated as described in statistical methods.   908 
 909 
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Figure legends 910 
 911 
Figure 1 - Primer details and PCR products. 912 
A-   The primers used for each exon PCR (Ex1-Ex4) are detailed for their forward (F) 913 
and reverse (1R) order along with the respective melting temperature (Tm), annealing 914 
temperature (Ta) and the amplified DNA fragment size.  915 
B - PCR amplification of each LGALS13 exons (Ex1-Ex4) presented after separation 916 
on Gel electrophoresis. M - 100bp DNA marker 917 
 918 
Figure 2 – Sequencing of the -98 Site. 919 
A – A multiple sequence alignment of the PCR products of exon 1 from several 920 
specimens, including LGALS13 promoter region and flanking intron. 921 
B – Enlarged vision of 20 nucleotides including the -98 position (peaks after the black 922 
vertical line). On top – the subject marked in section A that carries the A/A genotype. 923 
The two rows below show additional subjects with C/C genotype (middle) and A/C 924 
genotype (bottom).  925 
 926 
Figure 3 – Promoter luciferase assays. 927 
A – Partial promoter sequence of LGALS13. Nucleotide positions from the translation 928 
initiator codon (underlined) are shown in the left. The first exon is shown with bold 929 
black, the predicted TFAP2A binding site is depicted by bold blue underlined letters, 930 
and the “C” in -98 position is highlighted with red. 931 
B – Positional Probability Matrix (PPM) and Positional Weight Matrix (PWM) of the 932 
canonical TFAP2A binding site (MA0003.1) as downloaded from the Jaspar database 933 
(http://jaspar.genereg.net/). PPM values provide the normalized occurrence of each 934 
nucleotide at each position in the canonical TFAP2A binding site, while PWM – log- 935 
likelihood ratio derived from PPM – values provide binding affinity scores for each 936 
nucleotide at each position. The most frequent nucleotides in each position in the 937 
PPM are depicted with values colored according to the coloring of nucleotides in the 938 
PWM. As shown with red square, the „C” in the fourth position of the TFAP2A 939 
binding site has a higher occurrence, and thus affinity, than “A”. C – Luciferase 940 
activity of “-98C” and “-98A” LGALS13 promoter clones. Promoter “-98A" variant 941 
had 13% lower expression in non-differentiated BeWo cells (p=0.04) and 26% lower 942 
 44 
expression in Forskolin-induced BeWo cells after 48 hours of differentiation 943 
(p<0.001) than the “-98C" variant. While the expression of both promoter variants 944 
increased during the 48 hours of differentiation, the "-98C" variant had 4.55-fold 945 
increase while the "-98A" variant had only 3.85-fold increase in expression (-15%, 946 
p<0.001). All experiments were run in triplicate. 947 
948 
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Figure 3: Promoter luciferase assays 952 
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